Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Orgenesis Inc (ORGS)

Orgenesis Inc (ORGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 9,647
  • Shares Outstanding, K 4,799
  • Annual Sales, $ 530 K
  • Annual Income, $ -55,360 K
  • EBIT $ -56 M
  • EBITDA $ -55 M
  • 60-Month Beta 0.72
  • Price/Sales 10.59
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.13
  • Most Recent Earnings $-1.93 on 11/13/24
  • Next Earnings Date 05/20/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7600 +14.20%
on 05/08/25
2.5800 -22.09%
on 04/21/25
-0.1800 (-8.22%)
since 04/17/25
3-Month
1.5200 +32.24%
on 02/21/25
5.8900 -65.87%
on 02/28/25
+0.3501 (+21.09%)
since 02/20/25
52-Week
0.8700 +131.03%
on 12/18/24
10.7990 -81.39%
on 08/14/24
-3.4930 (-63.47%)
since 05/20/24

Most Recent Stories

More News
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments

ORGS : 2.0100 (unch)
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

Funding Aimed at Accelerating Rollout of Decentralized CGT Platform

ORGS : 2.0100 (unch)
Orgenesis Provides Third Quarter 2024 Business Update

ORGS : 2.0100 (unch)
Orgenesis Commences Trading on OTCQX® Best Market

ORGS : 2.0100 (unch)
Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...

ORGS : 2.0100 (unch)
Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant

Focus is to Develop Cost-effective Production of Autologous Induced Pluripotent Stem Cells (iPSCs) using Microfluidic Technologies and Artificial...

ORGS : 2.0100 (unch)
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update

Orgenesis to host conference call today at 12:00 PM ET...

ORGS : 2.0100 (unch)
Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

Orgenesis achieves milestone in the placement of the Orgenesis Mobile Processing Units and Lab (OMPUL) for the development of cell and gene therapies at...

ORGS : 2.0100 (unch)
Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Center will expand Orgenesis’ Point of Care (POCare) Platform Capabilities in Maryland...

ORGS : 2.0100 (unch)
Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

Orgenesis to host conference call today at 8:30AM ET...

ORGS : 2.0100 (unch)

Business Summary

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing...

See More

Key Turning Points

3rd Resistance Point 2.0433
2nd Resistance Point 2.0367
1st Resistance Point 2.0233
Last Price 2.0100
1st Support Level 2.0033
2nd Support Level 1.9967
3rd Support Level 1.9833

See More

52-Week High 10.7990
Fibonacci 61.8% 7.0061
Fibonacci 50% 5.8345
Fibonacci 38.2% 4.6629
Last Price 2.0100
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar